About GlySure
GlySure is a company based in Abingdon (United Kingdom) founded in 2006. GlySure has raised $24.5 million across 2 funding rounds from investors including Amadeus Capital Partners, Delta Partners and Morningside China. The company has 41 employees. GlySure operates in a competitive market with competitors including ZOLL AEDs, Attune Medical, InnAccel, ART Medical and Glucoset, among others.
- Headquarter Abingdon, United Kingdom
- Employees 41
- SectorsHealthcare
- Website glysure.com
- Social LinkedIn X
- Legal Name Glysure Limited
- Total Equity Funding$24.5M (USD)
in 2 rounds
- Latest Funding Round$13.6M (USD), Series C
Nov 2012
- InvestorsAmadeus Capital Partners
& 3 more
- Employee Count41
Funding Insights of GlySure
GlySure has successfully raised a total of $24.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $13.6 million completed in November 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.5M
- Total Rounds 2
- Last Round Series C — $13.6M
- First Round $10.9M
(Jan 2012)
- Investors Count 4
All 2 funding rounds of GlySure with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2012 | $13.6M | Series C | – | – | |
| Jan 2012 | $10.9M | Series C | – | Morningside |
4 investors in total: 3 institutional and 1 angel.
Investors in GlySure
GlySure has secured backing from 4 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Amadeus Capital Partners, Delta Partners and Morningside China.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage deep technology investments are made by Amadeus Capital. | – | amadeuscapital.com | London, United Kingdom | |
Early stage venture capital is provided to Irish startups. | – | deltapartners.com | Ireland | |
VC and private equity investments are made in China-US companies. | – | morningside.com.cn | Shanghai, China | |
FA Frank A Bonsal | - | – | unknown_c0462643b2d84818a | - |
Investor details for GlySure
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GlySure
3 people are tracked at GlySure (2 in leadership, 1 in team); the tracked headcount is 41.
| Name | Role | Group |
|---|---|---|
Chris Jones | CEO | Leadership |
Paul Mather | Director Of Business Development Europe | Leadership |
Mark Evans | Development Manager | Team |
Complete people profiles for GlySure
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GlySure
3 dated milestones of GlySure across 6 years, from founding to its latest funding, stage changes and deals.
- Founded GlySure is founded.
- Funding First funding round of $10.9M.
- Funding Latest funding round, Series C, of $13.6M.
Competitors of GlySure
GlySure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZOLL AEDs, Attune Medical, InnAccel, ART Medical and Glucoset, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| zoll.com | 1983 | Chelmsford, United States | – | – | Medical devices and software for emergency care are developed. | |
| attune-medical.com | 2009 | Chicago, United States | $51.28M | – | Patient temperature is modulated via esophageal cooling devices. | |
| innaccel.com | 2012 | Bengaluru, India | $6.06M | 63 | Diversified medical devices are manufactured for critical and maternal care. | |
| artmedical.com | 2009 | Netanya, Israel | $20M | – | Safe enteral nourishment products for ICU patients are developed. | |
| glucoset.com | 2013 | Trondheim, Norway | $6.59M | 20 | Continuous intravascular blood glucose monitoring devices are developed. | |
| inspiration-healthcare.com | 1998 | Crawley, United Kingdom | – | 195 | Medical devices for intensive care units are developed. | |
| braincool.se | 2010 | Lund, Sweden | – | – | Brain cooling technologies and therapeutic hypothermia devices are developed. | |
| benechill.com | 2004 | San Diego, United States | $41.6M | 9 | Non-invasive cooling technologies for acute ischemic events are developed. |
Detailed competitors of GlySure
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glysure
Complete news archive for GlySure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to GlySure
10 companies that operate in the same segment as GlySure (Medical Equipment & Supplies), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Software and integrated solutions for surgical and radiotherapy applications | 1989 | Munchen, Bayern, Germany | USD 12.68 M | USD 1.18 M | 18 | |
Robotic waterjet system for prostate tissue removal is developed. | 2009 | Redwood City, California, United States | USD 348.84 M | USD 308.05 M | 756 | |
Collaborative surgical robotic systems are provided for hospital procedures. | 2014 | Cambridge, Cambridgeshire, United Kingdom | USD 1.32 B | – | – | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.17 M | – | 242 | |
Augmented reality systems for guiding surgical procedures are developed. | 2014 | Yokneam Illit, North District, Israel | USD 142.6 M | – | – | |
Manufacturer of imaging and surgical products | 1919 | Tokyo, Tokyo, Japan | – | USD 6.49 B | 35,933 | |
Injectable packaging, containment, and delivery solutions are manufactured. | 1923 | Exton, Pennsylvania, United States | – | USD 3.07 B | 10,600 | |
Rapid infusion systems are provided for critically ill patients. | 2012 | Durham, North Carolina, United States | USD 77.98 M | – | – | |
Mobile robots are manufactured for industries including healthcare and agriculture. | 2013 | Odense, Denmark | USD 81.44 M | – | 303 | |
Visualization systems for surgical procedures are developed using machine learning. | 2016 | Seattle, Washington, United States | USD 74.25 M | – | 52 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GlySure
GlySure was founded in 2006 and raised its 1st funding round 6 years after it was founded.
GlySure is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
GlySure is a funded company, having raised a total of $24.5M across 2 funding rounds to date. The company's 1st funding round was a Series C of $10.9M, raised on Jan 2012.
GlySure has 41 employees.
GlySure has developed a continuous intravascular (I.V) glucose monitoring system using a proprietary optical fluorescence sensor for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company claims to have demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patients stay in the ICU. Also, the company mentions that hospital TGC has shown in prospective outcomes trials to produce significant improvement in patient outcomes including 46 reduction in incidence of sepsis, 41 reduction in renal failure, and 34 reduction in mortality. As of December 2016, the Company is finalizing design of a clinical trial to support submission to the U.S. Food and Drug Administration (FDA).
GlySure's top competitors include ZOLL AEDs, Inspiration Healthcare and InnAccel.
GlySure has 4 investors. Key investors include Amadeus Capital Partners, Delta Partners, Morningside China, and Frank A Bonsal.
GlySure operates through Glysure Limited.